Reduced-dose chemotherapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed stage IV lung cancer (or stage III if you’re not a candidate for curative treatment).
- Your planned cancer treatment must include at least one chemotherapy drug, not just targeted therapy or immunotherapy.
- Your cancer must have measurable spots that can be tracked on scans.
- You must be 18 or older and able to sign consent forms.
- Your overall health/activity level must be in a range that doctors call ECOG 0 to 3.
- If you have brain metastases, they must be stable and you can’t need ongoing steroid treatment for them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for people with advanced non-small cell or small cell lung cancer that cannot be removed by surgery or cured with standard treatments. It aims to see if the combination is safe and effective.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This trial tests how well chemotherapy works for people with stage IV non-small cell lung cancer that has spread. It is for those who have already tried at least one prior treatment and are healthy enough for more therapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.